Urologic Oncology Articles

Abiraterone Shows Promise in Prostate Cancer After Hormone Induction Failure
Thomas Flaig, MD, discusses the study of abiraterone acetate in metastatic prostate cancer after hormone induction failure and its impact on future research in this setting.
ASCO Issues Guidance on Second-Line Treatment of CRPC
Informed by new clinical evidence, ASCO has issued updated guidance on the use of second-line hormonal therapy for chemotherapy-naïve patients with castration-resistant prostate cancer.
Expert Highlights Rapidly Evolving Biomarker Development in Prostate Cancer
Leonard Gomella, MD, discusses the future of biomarkers in prostate cancer.
Next-Generation Therapies in CRPC Take Aim at AR Resistance
As a wealth of research has shown in the past several years, therapies that target the androgen receptor pathway in patients with castration-resistant prostate cancer encounter complex mechanisms of resistance including the likelihood that more than 1 such signaling network is active in each individual.
The FDA has granted an accelerated approval to atezolizumab as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Dreicer Discusses Emerging Agents in mCRPC
Robert Dreicer, MD, highlights several emerging treatments for patients with metastatic castration-resistant prostate cancer. 

 
AR-V7 Predicts Response in Castration-Resistant Prostate Cancer
The presence of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells predicted poorer outcomes for men with castration-resistant prostate cancer assigned to novel hormonal therapies, according to results recently published in the Journal of Clinical Oncology.
USPSTF Could Drop Its Opposition to Routine Prostate Cancer Screening
The US Preventive Services Task Force may move away from its long-standing opposition to routine PSA screening for prostate cancer in some men.
RCC Advances Shake Up Drug Choices

Axitinib was a promising newcomer in the renal cell carcinoma field when it was introduced as a second-line therapy 5 years ago. Now it is being displaced by newer therapies, a development that may serve as a harbinger for the evolution of treatment patterns in other tumor types with a bounty of novel agents. 

Padmanee Sharma, MD, PhD, discusses the significance of the VISTA immune-checkpoint pathway in prostate cancer, and her proposed novel immunotherapy approach for patients with these tumors.
Publication Bottom Border
Border Publication